Please ensure Javascript is enabled for purposes of website accessibility

Biotech Losers: InterMune, Enanta, and GW Pharmaceuticals

By Dave Williamson and Max Macaluso – Feb 6, 2014 at 8:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what dragged down InterMune, Enanta, and GW Pharmaceuticals in the biotech space this week.

In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.

In this segment, a look at the biotech losers on the market during the last two days. InterMune (ITMN.DL) pulled back 10% yesterday, down a total of 22% during the last five trading sessions, as investors remain concerned about new competition for Esbriet, which is the company's idiopathic pulmonary fibrosis drug. Enanta Pharmaceuticals (ENTA 1.39%) is also down 10%, dragged down by the continuing investor excitement surrounding Gilead and its hepatitis C treatment. Enanta is partners with AbbVie and will get royalties off of AbbVie's own hep. C drug regimen, but investor enthusiasm may be siding with Gilead at the moment. David sees this battle as coming down to relative pricing, and will be watching that closely. And finally, GW Pharmaceuticals (GWPH) fell by 7% after reporting solid earnings that beat on the top line yesterday, after its tremendous run up of more than 500% in the past six months, David sees this as potentially a case of investors taking some profit off the table.

David Williamson owns shares of AbbVie. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

InterMune, Inc. Stock Quote
InterMune, Inc.
Enanta Pharmaceuticals Stock Quote
Enanta Pharmaceuticals
$45.24 (1.39%) $0.62
GW Pharmaceuticals Stock Quote
GW Pharmaceuticals

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.